nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00034216,Biospecimen Acquisition From Human Subjects,,Recruiting,Observational,Prostate Cancer; Breast Cancer; Colon Cancer; Lung Cancer; Liver Cancer,,,National Cancer Institute (NCI),,1750,2002-07-16,,United States,No,https://clinicaltrials.gov/study/NCT00034216
NCT01174121,"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors,Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL,,National Cancer Institute (NCI),,332,2010-08-26,2029-12-27,United States,No,https://clinicaltrials.gov/study/NCT01174121
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02172651,Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.,Early Phase 1,Recruiting,Interventional,"Stage, Colon Cancer; Stage I-III Colon Cancer; Stage IV Colon Cancer With Resectable Liver Metastases",Vitamin D3; Placebo,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); Pharmavite LLC,80,2014-07-14,2026-06-30,United States,No,https://clinicaltrials.gov/study/NCT02172651
NCT02448173,A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer,Phase 3,Not yet recruiting,Interventional,Stage II Colon Cancer,OncoVAX and Surgery; Surgery,,Vaccinogen Inc,,550,2026-08-05,2033-08-05,United States,No,https://clinicaltrials.gov/study/NCT02448173
NCT03203525,A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer,Phase 1,Recruiting,Interventional,Advanced Malignant Neoplasm; Colorectal Carcinoma Metastatic in the Liver; Metastatic Malignant Neoplasm in the Liver; Refractory Malignant Neoplasm,Bevacizumab; Fluorouracil; Leucovorin; Oxaliplatin; Pegylated Liposomal Doxorubicin Hydrochloride; Temsirolimus; Tumor Treating Fields Therapy,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),52,2020-06-23,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT03203525
NCT03260491,"A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),HER3-DXd (FL-DP); HER3-DXd (CTM-1 Lyo-DP); HER3-DXd (CTM-3 Lyo-DP),,Daiichi Sankyo,Merck Sharp & Dohme LLC,309,2017-10-30,2026-12-31,Japan; Netherlands; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT03260491
NCT03551951,"Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers and Subjects Undergoing Lung Cancer Screening",,Recruiting,Observational,Non Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Pancreatic Cancer; Hepatocellular Cancer; Colorectal Cancer,"Test for circulating tumor cells, DNA alterations",,University of Missouri-Columbia,Harry S. Truman Memorial Veterans' Hospital,320,2016-07-01,2027-12-30,United States,No,https://clinicaltrials.gov/study/NCT03551951
NCT03998202,Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study,,Recruiting,Observational,Colorectal Cancer; Sarcopenia,,,Wake Forest University Health Sciences,University of Alabama at Birmingham,300,2019-09-23,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT03998202
NCT04165772,A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors,Phase 2,Recruiting,Interventional,"Rectal Adenocarcinoma; Clinical Stage: Stage II (T3-4, N-); Stage III (Any T, N+); Solid Tumor; Solid Tumor, Adult",TSR-042 or Dostarlimab; capecitabine or 5-FU; Intensity Modulated Radiation Therapy (IMRT),,Memorial Sloan Kettering Cancer Center,"Tesaro, Inc.",200,2019-12-11,2026-11-30,United States,No,https://clinicaltrials.gov/study/NCT04165772
NCT04222413,"First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors; Metastatic Pancreatic Cancer; Pediatric Solid Tumor; Advanced Breast Cancer; Malignant Peripheral Nerve Sheath Tumor; Colorectal Neoplasms,Metarrestin,,National Cancer Institute (NCI),,116,2020-10-27,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT04222413
NCT04302025,"NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Alectinib; Entrectinib; Vemurafenib; Cobimetinib; Pralsetinib; Atezolizumab; SBRT; Resection; Chemotherapy; Divarasib,,"Genentech, Inc.",,99,2020-11-06,2030-05-30,United States,No,https://clinicaltrials.gov/study/NCT04302025
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04511039,A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers,Phase 1,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Clinical Stage III Gastroesophageal Junction Adenocarcinoma; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A; Locally Advanced Colorectal Carcinoma; Locally Advanced Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma; Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8,Trifluridine and Tipiracil Hydrochloride; Talazoparib Tosylate,,Roswell Park Cancer Institute,Pfizer; National Cancer Institute (NCI),45,2021-06-08,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT04511039
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Phase 2,Recruiting,Interventional,Solid Tumors,Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib,,Hoffmann-La Roche,,920,2021-01-18,2032-09-25,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; New Zealand; Poland; Portugal; Puerto Rico; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04589845
NCT04613596,A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2/Phase 3,Recruiting,Interventional,Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer,Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab,,Mirati Therapeutics Inc.,,806,2020-12-02,2029-10-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Finland; France; Georgia; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Norway; Peru; Philippines; Poland; Portugal; Romania; Serbia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04613596
NCT04633512,Safety and Feasibility of ActivSightTM Laser Speckle Imaging in Visualization of Tissue Perfusion and Vasculature in Human,Not Applicable,Enrolling by invitation,Interventional,"Acute Cholecystitis; Colorectal Cancer; Diverticulitis, Colonic; Obesity, Morbid; Inflammatory Bowel Diseases",ActivSight,,Activ Surgical,"The University of Texas Health Science Center, Houston; University at Buffalo; Ohio State University",67,2020-11-17,2025-01-05,United States,No,https://clinicaltrials.gov/study/NCT04633512
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04847063,"Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies",Phase 1,Recruiting,Interventional,Peritoneal Carcinomatosis; Peritoneal Mesothelioma; Ovarian Cancer; Gastrointestinal Cancer; Appendiceal Cancer,Mitomycin C; Cisplatin; Heated Intraperitonial Chemotherapy; Doxorubicin; Oxaliplatin; 5-Fluorouracil; Sodium Thiosulfate,,National Cancer Institute (NCI),,60,2021-10-19,2031-12-30,United States,No,https://clinicaltrials.gov/study/NCT04847063
NCT04899908,"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",Phase 2,Recruiting,Interventional,Brain Cancer; Brain Metastases; Melanoma; Lung Cancer; Breast Cancer; HER2-positive Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; SRS; SRT; Whole Brain Radiation; Stereotactic Radiation; AGuIX; Nanoparticle; Cystic; Brain Tumor,Stereotactic Radiation; AGuIX gadolinium-based nanoparticles; Placebo,,Dana-Farber Cancer Institute,NH TherAguix SAS,134,2021-09-15,2026-02-05,United States,No,https://clinicaltrials.gov/study/NCT04899908
NCT04929223,"A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",Phase 1,Recruiting,Interventional,Metastatic Colorectal Cancer,Inavolisib; Bevacizumab; Cetuximab; Atezolizumab; Tiragolumab; SY-5609; Divarasib; FOLFOX; FOLFIRI; FoundationOne®Liquid CDx,,Hoffmann-La Roche,,542,2021-10-22,2028-11-07,Australia; Canada; Denmark; Germany; Italy; Poland; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04929223
NCT04956640,A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms",LY3537982; Pembrolizumab; Cetuximab; Pemetrexed; Cisplatin; Carboplatin,,Eli Lilly and Company,Merck Sharp & Dohme LLC,540,2021-07-19,2027-04-05,Australia; Canada; France; Japan; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04956640
NCT05067283,"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,MK-1084; Pembrolizumab; carboplatin; pemetrexed; cetuximab; oxaliplatin; leucovorin; 5-fluorouracil,,Merck Sharp & Dohme LLC,,830,2021-12-17,2030-02-25,Australia; Canada; Chile; China; Denmark; Israel; Italy; Japan; Lithuania; Malaysia; New Zealand; Panama; Poland; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05067283
NCT05074810,A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; KRAS Activating Mutation,avutometinib and sotorasib; avutometinib and sotorasib and defactinib,,"Verastem, Inc.",Amgen,153,2022-04-12,2027-04-05,Belgium; France; Netherlands; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05074810
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05204147,A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers,Phase 1,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer,Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A; Biospecimen Collection,,City of Hope Medical Center,National Cancer Institute (NCI),20,2022-06-02,2026-07-21,United States,No,https://clinicaltrials.gov/study/NCT05204147
NCT05254184,Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,12,2022-11-01,2027-04-01,United States,No,https://clinicaltrials.gov/study/NCT05254184
NCT05405595,"A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced/Metastatic Solid Tumors,ADG126; Pembrolizumab (KEYTRUDA®); Standard of Care (Trifluridine/Tipiracil-Bevacizumab); Standard of care (Fruquintinib),,Adagene Inc,Merck Sharp & Dohme LLC,152,2022-06-15,2027-04-30,China; South Korea; United States,No,https://clinicaltrials.gov/study/NCT05405595
NCT05410145,"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,KRAS P.G12C,D3S-001; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Cetuximab,,"D3 Bio (Wuxi) Co., Ltd",,442,2022-08-03,2027-04-05,Australia; China; France; Germany; Hong Kong; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT05410145
NCT05609578,A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced NSCLC; Metastatic Lung Cancer,Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin,,Mirati Therapeutics Inc.,,90,2022-11-22,2026-12-01,Brazil; Chile; France; Georgia; Greece; Hungary; Italy; Malaysia; Poland; Serbia; Spain; Switzerland; Thailand; United States,No,https://clinicaltrials.gov/study/NCT05609578
NCT05638295,A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial,Phase 2,Recruiting,Interventional,Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Panitumumab; Sotorasib,,National Cancer Institute (NCI),,105,2024-08-01,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT05638295
NCT05722288,"A Randomized, Phase II Clinical Trial of Time-Restricted Eating Versus Nutritional Counseling in Cancer Patients Receiving Radiation or Chemoradiation to Evaluate Its Impact on Toxicity and Efficacy",Phase 2,Recruiting,Interventional,Localized Prostate Carcinoma; Locally Advanced Cervical Carcinoma; Locally Advanced Rectal Carcinoma; Malignant Solid Neoplasm; Recurrent Prostate Carcinoma; Stage I Prostate Cancer AJCC v8; Stage IB Cervical Cancer FIGO 2018; Stage IB2 Cervical Cancer FIGO 2018; Stage II Prostate Cancer AJCC v8; Stage II Rectal Cancer AJCC v8; Stage IIA Cervical Cancer FIGO 2018; Stage IIB Cervical Cancer FIGO 2018; Stage III Prostate Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC Cervical Cancer FIGO 2018; Stage IVA Prostate Cancer AJCC v8,Biospecimen Collection; Informational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Short-Term Fasting,,City of Hope Medical Center,National Cancer Institute (NCI),60,2023-01-20,2026-07-20,United States,No,https://clinicaltrials.gov/study/NCT05722288
NCT05780684,"Adaptive, Individualized Dose Escalation of Fluorouracil-Based Chemotherapy for Gastrointestinal Cancer: Pilot Study of the FOX Regimen",Not Applicable,Recruiting,Interventional,Colorectal Cancer; Esophagus Cancer; Appendix Cancer; Small Bowel Cancer; Ampullary Cancer,FOX dose-escalation algorithm,,Dartmouth-Hitchcock Medical Center,,36,2023-07-14,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT05780684
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05789082,"A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Divarasib; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed,,Hoffmann-La Roche,,320,2023-06-20,2032-01-29,Argentina; Australia; Belgium; Brazil; Canada; China; Israel; Italy; Japan; Netherlands; Poland; South Korea; Spain; Sweden; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05789082
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05853575,A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation,Phase 2,Recruiting,Interventional,Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung,Adagrasib,,Mirati Therapeutics Inc.,,200,2024-02-16,2026-07-30,Brazil; Croatia; France; Greece; Hungary; Israel; Italy; Japan; Mexico; Netherlands; Peru; Poland; Romania; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT05853575
NCT05920356,"A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC),Sotorasib; Pembrolizumab,,Amgen,,750,2023-11-16,2031-06-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Latvia; Malaysia; Mexico; Netherlands; Peru; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05920356
NCT05952557,"CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease",Phase 3,Recruiting,Interventional,"Breast Cancer, Early Breast Cancer",Camizestrant; Tamoxifen; Anastrozole; Letrozole; Exemestane; Abemaciclib,,AstraZeneca,Austrian Breast and Colorectal Cancer Study Group (ABCSG),5500,2023-10-05,2037-05-06,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Estonia; France; Georgia; Germany; Greece; Hungary; India; Ireland; Israel; Italy; Japan; Malaysia; Mexico; New Zealand; Peru; Philippines; Poland; Portugal; Puerto Rico; Romania; Saudi Arabia; Serbia; South Africa; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05952557
NCT05961709,The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer,Phase 2,Recruiting,Interventional,Colon Cancer,Cemiplimab,,M.D. Anderson Cancer Center,Regeneron Pharmaceuticals,50,2024-05-20,2028-04-30,United States,No,https://clinicaltrials.gov/study/NCT05961709
NCT06026410,"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC),Darlifarnib; Cabozantinib; Adagrasib,,"Kura Oncology, Inc.",Mirati Therapeutics Inc.,300,2023-10-18,2027-04-05,France; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT06026410
NCT06037837,Generalized Robotic Skills Assessment Using Machine Learning-Based Analysis Across Multiple Surgical Specialties,,Enrolling by invitation,Observational,Surgery,Robotic Surgery,,Memorial Sloan Kettering Cancer Center,,1000,2023-08-24,2026-08-24,United States,No,https://clinicaltrials.gov/study/NCT06037837
NCT06096623,The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparities in Cancer Treatment Delay,Not Applicable,Recruiting,Interventional,Cancer; Breast Cancer; Colorectal Cancer,Weekly Survey,,UNC Lineberger Comprehensive Cancer Center,,240,2023-11-06,2026-05-05,United States,No,https://clinicaltrials.gov/study/NCT06096623
NCT06119581,"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis",LY3537982; Pembrolizumab; Placebo; Cisplatin; Carboplatin; Pemetrexed,,Eli Lilly and Company,,1016,2023-12-21,2029-10-05,Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Hungary; India; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06119581
NCT06128551,"Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma,Assigned interventions,,"Revolution Medicines, Inc.",,210,2023-11-14,2026-11-30,France; Germany; Italy; Netherlands; Puerto Rico; Spain; United States,No,https://clinicaltrials.gov/study/NCT06128551
NCT06130254,"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Non-small Cell Lung Cancers,Adagrasib; Olaparib,,M.D. Anderson Cancer Center,Mirati Therapeutics Inc.,52,2024-01-30,2030-08-25,United States,No,https://clinicaltrials.gov/study/NCT06130254
NCT06131840,An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors,Phase 1,Recruiting,Interventional,"Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms; Pancreatic Ductal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Small Cell Lung Carcinoma",PF-08046050; bevacizumab; 5-Fluorouracil (5-FU); Oxaliplatin; Leucovorin (LV),,"Seagen, a wholly owned subsidiary of Pfizer",Sanofi,914,2023-11-20,2030-09-12,Canada; France; Netherlands; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06131840
NCT06149481,"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer,"Retifanlimab; Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform; N-803; SX-682",,National Cancer Institute (NCI),,60,2024-03-26,2030-10-31,United States,No,https://clinicaltrials.gov/study/NCT06149481
NCT06162221,A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC),Phase 1/Phase 2,Recruiting,Interventional,"Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC",RMC-6291; RMC-6236; Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; RMC-9805,,"Revolution Medicines, Inc.",,616,2024-01-18,2028-12-05,Australia; Denmark; France; Germany; Greece; Italy; Netherlands; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06162221
NCT06244771,"An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Advanced Solid Tumors With KRAS G12C Mutations; Solid Tumor, Adult; Unresectable Solid Tumor; Metastatic Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer; KRAS G12C; Pancreatic Cancer",FMC-376,,Frontier Medicines Corporation,,403,2024-02-12,2028-04-05,Australia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06244771
NCT06248606,Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; NSCLC; KRAS G12C,Adagrasib; Stereotactic Radiosurgery,,"Ryan Gentzler, MD",Mirati Therapeutics Inc.; University of Virginia,30,2024-08-06,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT06248606
NCT06249282,A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Biopsy; Biospecimen Collection; Carfilzomib; Computed Tomography; Echocardiography; Magnetic Resonance Imaging; Sotorasib,,City of Hope Medical Center,National Cancer Institute (NCI),15,2024-04-24,2026-03-19,United States,No,https://clinicaltrials.gov/study/NCT06249282
NCT06252649,"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",Phase 3,Recruiting,Interventional,Metastatic Colorectal Cancer,FOLFIRI Regimen; Sotorasib; Panitumumab; Bevacizumab-awwb,,Amgen,,450,2024-07-17,2031-08-31,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; Colombia; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06252649
NCT06270706,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor,PLN-101095; Pembrolizumab,,"Pliant Therapeutics, Inc.",,77,2023-08-30,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06270706
NCT06333951,"A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",Phase 1,Recruiting,Interventional,Thoracic Tumors; Non-small Cell Lung Cancer,AMG 193; Carboplatin; Paclitaxel; Pembrolizumab; Pemetrexed; Sotorasib,,Amgen,,500,2024-09-17,2031-10-27,Argentina; Australia; Austria; Belgium; Brazil; Canada; China; France; Germany; Greece; Hong Kong; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06333951
NCT06342401,Development and Validation fo an Exosome-Based and Machine Learning Powered Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer,,Recruiting,Observational,Colorectal Cancer; Colorectal Neoplasms; Colorectal Adenocarcinoma; Colorectal Cancer Stage I; Colorectal Cancer Stage IV; Colorectal Cancer Stage II; Colorectal Cancer Stage III; Colorectal Neoplasms Malignant,ENCODE,,City of Hope Medical Center,,400,2023-04-15,2025-10-15,Italy; Japan; Spain; United States,No,https://clinicaltrials.gov/study/NCT06342401
NCT06343402,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; NSCLC; KRAS G12C; Metastatic Lung Cancer; Advanced Lung Carcinoma,BBO-8520; Pembrolizumab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,250,2024-05-22,2028-02-05,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06343402
NCT06345729,"A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Placebo; Pembrolizumab,,Merck Sharp & Dohme LLC,,600,2024-05-24,2031-02-18,Argentina; Australia; Austria; Brazil; Bulgaria; Canada; Chile; China; France; Georgia; Germany; Greece; India; Italy; Japan; Mexico; Netherlands; New Zealand; Philippines; Poland; Romania; South Korea; Spain; Turkey (Türkiye); Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06345729
NCT06371768,Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors,Not Applicable,Recruiting,Interventional,Cancer; Breast Cancer; Colorectal Cancer; Sarcoma; Lymphoma; Testicular Cancer,AYA Educational Information; AYA STEPS,,Duke University,National Cancer Institute (NCI),260,2025-07-14,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06371768
NCT06403436,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Adult Solid Tumor; Adult Disease; Cancer; NSCLC; EGFR; KRAS G12C; Squamous Cell Lung Cancer,TT125-802,,TOLREMO therapeutics AG,,50,2023-11-07,2026-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06403436
NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; KRAS G12C Mutations,Cetuximab; Cemiplimab; Adagrasib,,M.D. Anderson Cancer Center,,31,2024-08-28,2028-03-01,United States,No,https://clinicaltrials.gov/study/NCT06412198
NCT06447662,A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene,Phase 1,Recruiting,Interventional,"Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung",PF-07934040; Gemcitabine; Nab-paclitaxel; Cetuximab; Fluorouracil; Oxaliplatin; Leucovorin; Bevacizumab; Pembrolizumab; pemetrexed; Cisplatin; Paclitaxel; Carboplatin,,Pfizer,,330,2024-06-27,2028-09-09,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT06447662
NCT06462521,Cold Snare Piecemeal Resection vs Cold Snare Endoscopic Mucosal Resection: A RandomizeD Trial IN Colorectal Adenomas 10-19mm and Serrated Lesions ≥ 10mm (CARDINAL Study),Not Applicable,Enrolling by invitation,Interventional,Colon Cancer; Colon Polyp; Colon Adenoma; Serrated Polyp,Cold Snare Piecemeal Resection (CSPR); Cold Snare Endoscopic Mucosal Resection (Cold EMR),,Indiana University,"Rush University Medical Center; University of Colorado, Denver; John D. Dingell VA Medical Center; White River Junction Veterans Affairs Medical Center; University of Kansas Medical Center; Vancouver Coastal Health; Université de Montréal; University of Alabama at Birmingham",570,2024-09-06,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT06462521
NCT06562192,"Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers",Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; HR+/HER2- Ductal and Lobular Breast Cancer; Triple Negative Breast Cancer; Colorectal Cancer,[68Ga]Ga-NNS309; [177Lu]Lu-NNS309,,Novartis Pharmaceuticals,,162,2024-10-15,2031-01-16,Belgium; Canada; France; Germany; Israel; Italy; Netherlands; Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06562192
NCT06582771,A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Non Small Lung Cancer,Sotorasib,,Memorial Sloan Kettering Cancer Center,,39,2024-08-30,2026-08-05,United States,No,https://clinicaltrials.gov/study/NCT06582771
NCT06607185,A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,Phase 1,Recruiting,Interventional,Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor,LY4066434.; Cetuximab; Nab paclitaxel; Gemcitabine; Oxaliplatin; Leucovorin; Irinotecan; 5Fluorouracil; Carboplatin; Cisplatin; Pemetrexed; Pembrolizumab,,Eli Lilly and Company,,750,2024-10-21,2030-01-05,Belgium; China; France; Germany; Italy; Japan; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06607185
NCT06634875,"A Phase IIa, Non-Randomized, Open-Label Dose Expansion Trial of Isunakinra in Combination With Pembrolizumab in Patients With Metastatic or Unresectable, Locally Advanced Colorectal Cancer",Phase 2,Recruiting,Interventional,Colorectal Cancer Metastatic,isunakinra,,Buzzard Pharmaceuticals,,20,2025-01-30,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06634875
NCT06720987,"A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations",Phase 1,Recruiting,Interventional,KRAS G12C Mutation; KRAS G12S Mutation; Solid Tumor Malignancies; CRC (Colorectal Cancer),KQB365; Cetuximab,,Kumquat Biosciences Inc.,,128,2025-02-04,2030-06-30,United States,No,https://clinicaltrials.gov/study/NCT06720987
NCT06730750,"A Phase 1/2a, Multicenter, Open-label, First in Human Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,BMS-986490; Bevacizumab,,Bristol-Myers Squibb,,360,2025-02-12,2029-12-09,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06730750
NCT06746012,Designing a Dyad-Based MHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers: Human-Centered Study,Not Applicable,Recruiting,Interventional,Stage I Colon Cancer AJCC V8; Stage I Rectal Cancer AJCC V8; Stage II Colon Cancer AJCC V8; Stage II Rectal Cancer AJCC V8; Stage III Colon Cancer AJCC V8; Stage III Rectal Cancer AJCC V8,Discussion; Educational Activity; Internet-Based Intervention; Internet-Based Intervention; Interview; Medical Device Usage and Evaluation; Questionnaire Administration; Supportive Care; Survey Administration,,Ohio State University Comprehensive Cancer Center,,70,2024-05-03,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06746012
NCT06793215,"A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer,Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin,,Hoffmann-La Roche,Chugai Pharmaceutical,600,2025-10-24,2030-10-31,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Hungary; Italy; Netherlands; New Zealand; Poland; Portugal; Singapore; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06793215
NCT06804824,"A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,VVD-159642; Sotorasib; Trametinib,,"Vividion Therapeutics, Inc.",,220,2025-02-25,2027-08-01,Australia; United States,No,https://clinicaltrials.gov/study/NCT06804824
NCT06807619,BrainMet ADePPT (Anticancer Drug Penetration Platform Trial),Phase 1,Recruiting,Interventional,Brain Tumor,Sotorasib,,Memorial Sloan Kettering Cancer Center,Amgen,16,2025-01-29,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT06807619
NCT06822530,PROACT: Promoting Follow-Up of Abnormal Colorectal Cancer Screening Tests Through Multilevel Interventions,Not Applicable,Enrolling by invitation,Interventional,Colorectal Carcinoma,Best Practice; Educational Intervention; Electronic Health Record Review; Interview; Supportive Care; Survey Administration,,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),682,2025-12-16,2029-11-30,United States,No,https://clinicaltrials.gov/study/NCT06822530
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin,,Mirati Therapeutics Inc.,,630,2025-04-24,2032-04-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06875310
NCT06880055,Shield Post-Approval Study Protocol,,Recruiting,Observational,Colo-rectal Cancer,Shield Blood Test for colo-rectal cancer Screening,,"Guardant Health, Inc.",,3375,2025-07-14,2030-12-01,United States,No,https://clinicaltrials.gov/study/NCT06880055
NCT06881784,"RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",Phase 3,Recruiting,Interventional,NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC; NSCLC (Non-small Cell Lung Carcinoma); NSCLC (Advanced Non-small Cell Lung Cancer),daraxonrasib; docetaxel,,"Revolution Medicines, Inc.",,420,2025-05-06,2030-12-01,Australia; Belgium; France; Germany; Hong Kong; Ireland; Italy; Japan; Netherlands; Poland; Puerto Rico; Singapore; South Korea; Spain; Switzerland; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT06881784
NCT06883838,Enhancing Primary Care Capacity for Cancer Survivorship Care Delivery in Community Health Clinics,Not Applicable,Enrolling by invitation,Interventional,Cancer Survivorship,Survivorship care delivery intervention,,"The University of Texas Health Science Center, Houston",National Cancer Institute (NCI),5584,2025-09-01,2029-05-31,United States,No,https://clinicaltrials.gov/study/NCT06883838
NCT06890598,"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Olomorasib; Pembrolizumab; Durvalumab; Placebo,,Eli Lilly and Company,AstraZeneca,700,2025-03-27,2032-02-05,Australia; Austria; Belgium; Brazil; Chile; China; Czechia; France; Germany; Greece; Hungary; India; Israel; Italy; Japan; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06890598
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06917079,"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",Phase 1,Recruiting,Interventional,"Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult",BBO-11818; Pembrolizumab; Platinum chemotherapy (cisplatin or carboplatin); Pemetrexed; Cetuximab,,"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",,287,2025-03-31,2029-09-05,United States,No,https://clinicaltrials.gov/study/NCT06917079
NCT06995898,The Vanguard Study: Testing a New Way to Screen for Cancer,Not Applicable,Recruiting,Interventional,Bladder Carcinoma; Breast Carcinoma; Colorectal Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Liver Carcinoma; Lung Carcinoma; Malignant Solid Neoplasm; Ovarian Carcinoma; Pancreatic Carcinoma; Prostate Carcinoma,Biospecimen Collection; Device Usage; Electronic Health Record Review; Multi-Cancer Detection Test; Multi-Cancer Detection Test; Questionnaire Administration,,National Cancer Institute (NCI),,24000,2025-06-16,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06995898
NCT06997497,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)",Phase 3,Recruiting,Interventional,Colon Adenocarcinoma; Rectal Adenocarcinoma,MK-1084; Oxaliplatin; Leucovorin/levofolinate calcium; 5-Fluorouracil; Cetuximab; Bevacizumab; Bevacizumab biosimilar,,Merck Sharp & Dohme LLC,,477,2025-07-16,2030-10-27,Argentina; Australia; Brazil; China; Finland; France; Germany; Hong Kong; Israel; Japan; Netherlands; Poland; Romania; South Korea; Spain; Taiwan; Ukraine; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06997497
NCT07023731,"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,KRAS G12D Mutation; Advanced Solid Cancer,ARV-806,,Arvinas Inc.,,159,2025-05-29,2029-04-02,United States,No,https://clinicaltrials.gov/study/NCT07023731
NCT07046585,Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC),,Recruiting,Observational,Colo-rectal Cancer,,,"Natera, Inc.",,25000,2025-05-30,2033-09-30,United States,No,https://clinicaltrials.gov/study/NCT07046585
NCT07094204,A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications,Phase 1,Recruiting,Interventional,Solid Tumor; Non-Small-Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer,ASP5834; panitumumab,,Astellas Pharma Inc,,364,2025-07-25,2029-04-30,United States,No,https://clinicaltrials.gov/study/NCT07094204
NCT07115875,Improving Rates of Diagnostic Colonoscopy in Native Americans Through a Culturally Sensitive Digital Outreach Intervention,Not Applicable,Not yet recruiting,Interventional,CRC Screening; CRC (Colorectal Cancer),Digital Outreach; In Person consultation,,University of Oklahoma,,164,2025-12-05,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT07115875
NCT07141706,"A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced/Metastatic Solid Tumors,DB-1317,,DualityBio Inc.,,233,2025-09-23,2028-06-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT07141706
NCT07190248,"A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,MK-1084; Pembrolizumab (+) Berahyaluronidase alfa; Pemetrexed; Cisplatin; Carboplatin,,Merck Sharp & Dohme LLC,,675,2025-10-08,2032-08-06,Australia; Austria; Hungary; Israel; Japan; Romania; South Korea; Spain; Taiwan; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT07190248
NCT07209111,"A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)",Phase 2,Recruiting,Interventional,Neoplasm Malignant,MK-1084; Cetuximab,,Merck Sharp & Dohme LLC,,150,2025-12-04,2032-04-09,Denmark; Israel; Norway; South Korea; Spain; Sweden; United States,No,https://clinicaltrials.gov/study/NCT07209111
NCT07217171,"A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas",Phase 1,Recruiting,Interventional,Bladder Cancer; Squamous Cell Carcinoma of the Lung; Esophageal Squamous Cell Carcinoma; Tongue Squamous Cell Carcinoma; Cutaneous Squamous Cell Cancer; Penile Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Vulvar Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Vaginal Squamous Cell Carcinoma; Urethral Squamous Cell Carcinoma,EVOLVE104; EVOLVE104,,"EvolveImmune United, Inc",,160,2025-11-13,2031-01-29,United States,No,https://clinicaltrials.gov/study/NCT07217171
NCT07219537,Pilot Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule,Not Applicable,Recruiting,Interventional,Lynch Syndrome; Crohn Disease; Inflammatory Bowel Diseases; Healthy,Feasibility of using an OCT-based Retrograde Tethered Capsule Endomicroscope device to image the lower GI tract,,Massachusetts General Hospital,The Leona M. and Harry B. Helmsley Charitable Trust; Dana-Farber Cancer Institute,30,2023-03-27,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT07219537
NCT07221058,Adaptive Radiation BOost for Rectal Cancer: a Phase I Dose Escalation Study (ARBOR),Phase 1,Recruiting,Interventional,"Rectum Cancer, Adenocarcinoma",Adaptive Radiotherapy Boost,,Fox Chase Cancer Center,Varian Medical Systems,37,2025-10-24,2029-11-01,United States,No,https://clinicaltrials.gov/study/NCT07221058
NCT07221357,"ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer",Phase 2/Phase 3,Recruiting,Interventional,"Untreated, Unresectable, or Metastatic Colorectal Cancer",Pumitamig; FOLFOX; FOLFIRI; Bevacizumab; CAPOX,,Bristol-Myers Squibb,BioNTech SE,990,2026-03-04,2034-03-11,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; India; Italy; Japan; Netherlands; Poland; Romania; Singapore; South Korea; Spain; Sweden; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07221357
NCT07223047,"A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC),BMS-986523; Gemcitabine; Nab-Paclitaxel; Cetuximab; Pembrolizumab,,Bristol-Myers Squibb,,252,2025-11-25,2028-10-13,Canada; Spain; United States,No,https://clinicaltrials.gov/study/NCT07223047
NCT07223424,Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune),Phase 2,Recruiting,Interventional,Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Colo-rectal Cancer (dMMR/MSI-H CRC); Hepatocellular Carcinoma; Ulcerative Colitis; Esophageal Cancer; Squamous Cell Carcinoma; Gastric/GEJ; Cervical Cancer; Gastro-Esophageal Adenocarcinoma; Esophageal Adenocarcinoma,nivolumab; pembrolizumab,,Diwakar Davar,,480,2025-11-04,2030-11-30,United States,No,https://clinicaltrials.gov/study/NCT07223424
NCT07225309,Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer,Not Applicable,Not yet recruiting,Interventional,Breast Cancer; Prostate Cancer; Colorectal Cancer; Thyroid Cancer; Breast Cancer Stage III; Breast Cancer Stage IV; Prostate Cancer Stage III; Prostate Cancer Stage IV; Colorectal Cancer Stage III; Colorectal Cancer Stage IV; Thyroid Cancer Stage III; Thyroid Cancer Stage IV,Meaning-Centered Psychotherapy for Latinos /MCP-L,,Memorial Sloan Kettering Cancer Center,,300,2026-01-05,2029-04-13,United States,No,https://clinicaltrials.gov/study/NCT07225309
NCT07227025,A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer,Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Amivantamab; Olomorasib,,"Janssen Research & Development, LLC",,60,2025-12-22,2028-11-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT07227025
NCT07262619,"A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors",Phase 1/Phase 2,Not yet recruiting,Interventional,Advanced Solid Tumors; MSI-H or dMMR Advanced Solid Tumors; MSI-H/dMMR Gastric Cancer; MSI-H/dMMR Colorectal Cancer; MSI-H/dMMR Gastroesophageal-junction Cancer; Endometrial Cancer; Mismatch Repair Deficient or MSI-High Solid Tumors,EIK1005; Pembrolizumab (KEYTRUDA® ),,Eikon Therapeutics,,160,2025-12-05,2029-03-05,Australia; United States,No,https://clinicaltrials.gov/study/NCT07262619
NCT07288034,Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP),Phase 2,Not yet recruiting,Interventional,Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8,Adagrasib; Anti-PD-L1 Monoclonal Antibody; Anti-PD1 Monoclonal Antibody; Bevacizumab; Biopsy Procedure; Biospecimen Collection; Chemotherapy; Computed Tomography; Durvalumab; Magnetic Resonance Imaging; Monitoring; Positron Emission Tomography; Surveillance; Tremelimumab,,City of Hope Medical Center,National Cancer Institute (NCI),535,2026-09-21,2028-09-22,United States,No,https://clinicaltrials.gov/study/NCT07288034
